Skip to main content
Premium Trial:

Request an Annual Quote

Human Longevity Inks Deal with King's College London to Access TwinsUK Registry

NEW YORK (GenomeWeb) – Human Longevity today announced a collaboration with King's College London to access and sequence the college's TwinsUK Registry.

The San Diego-based sequencing and analytics firm will sequence whole genomes and microbiomes of up to 2,000 individuals, as well as conduct metabolomics analysis on up to 6,000 longitudinal samples in the database.

Containing more than 11,000 twin individuals, the TwinsUK Registry is "one of the largest and best characterized databases of individuals in the world," Human Longevity Co-founder and CEO Craig Venter said in a statement. Access to the phenotype information paired with the genomic and microbome samples "will enable the teams to collaborate on identifying correlations between phenotypes and genetic predisposition to health and disease," he said.

Human Longevity is building a database of human genotypes and phenotypes to help solve age-associated disease and human biological decline, as well as find commercialization opportunities in developing new diagnostics and therapeutics. The firm said it is currently sequencing and analyzing 2,000 genomes per month using Illumina's HiSeq X Ten instruments.

"The next-generation sequencing and analysis expertise of [Human Longevity], plus the unique data and design of the twin study, provides the perfect platform to unlock the clues to aging-related diseases and personalized medicine," Tim Spector, director of the TwinsUK Registy and professor of genetic epidemiology at King's College London, said.

Financial details were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.